TISSUE REPAIR LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 AUD | -4.35% |
|
-12.00% | 0.00% |
| Feb. 29 | Tissue Repair Limited Announces Change of Company Secretary | CI |
| Feb. 28 | Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 172K 115K | Sales 2023 | 972K 649K | Capitalization | 16.33M 10.9M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -4.01M | Net income 2023 | -4M -2.67M | EV / Sales 2022 | -60.1 x |
| Net cash position 2022 | 25.46M 16.99M | Net cash position 2023 | 21.4M 14.28M | EV / Sales 2023 | -5.22 x |
| P/E ratio 2022 |
-1.82
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.68% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.35% | ||
| 1 week | -12.00% | ||
| Current month | -12.00% | ||
| 3 months | -6.38% | ||
| 6 months | -12.00% |
1 week
0.22
0.24
1 month
0.220.25
Current year
0.220.26
1 year
0.210.35
3 years
0.200.83
5 years
0.200.83
10 years
0.200.83
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Jones
DFI | Director of Finance/CFO | - | - |
Mark Waring
CTO | Chief Tech/Sci/R&D Officer | - | - |
Darryl Reed
COO | Chief Operating Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 21-08-12 | |
Tony Charara
FOU | Founder | - | 11-12-31 |
| Director/Board Member | - | 21-10-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 0.22 | -4.35% | 115,760 |
| 24-05-13 | 0.23 | 0.00% | 8,120 |
| 24-05-10 | 0.23 | -2.13% | 51,381 |
| 24-05-09 | 0.235 | -6.00% | 25,022 |
| 24-05-07 | 0.25 | 0.00% | 4,679 |
Delayed Quote Australian S.E., May 13, 2024 at 11:55 pm EDT
More quotes
Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 8.81M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.44% | 21.25B | |
| -5.24% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +37.57% | 12.54B | |
| -26.24% | 8.09B |
- Stock Market
- Equities
- TRP Stock
